Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)

被引：0

作者：

Stilgenbauer, Stephan ^{[1
]}

Morschhauser, Franck ^{[2
]}

Wendtner, Clemens-Martin ^{[3
]}

Cartron, Guillaume ^{[4
]}

Hallek, Michael ^{[5
,6
]}

Eichhorst, Barbara ^{[7
]}

Kozloff, Mark F. ^{[8
]}

Giever, Thomas ^{[9
]}

Lozanski, Gerard ^{[10
]}

Jiang, Yanwen ^{[11
]}

Huang, Huang ^{[12
]}

Pignataro, Daniela Soriano ^{[13
]}

Schary, William ^{[14
]}

Humphrey, Kathryn ^{[15
]}

Mobasher, Mehrdad ^{[11
]}

Salles, Gilles ^{[16
]}

机构：

[1] Ulm Univ, Dept Internal Med 3, Ulm, Germany

[2] Univ Lille 2, Ctr Hosp Univ, Hematol, Lille, France

[3] Klinikum Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany

[4] Univ Hosp Montpellier, Dept Clin Hematol, Montpellier, France

[5] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[6] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, Cologne, Germany

[7] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[8] Univ Chicago Med, Chicago, IL USA

[9] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA

[10] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA

[11] Genentech Inc, San Francisco, CA 94080 USA

[12] F Hoffmann La Roche Ltd, Mississauga, ON, Canada

[13] Roche Prod Ltd, Welwyn Garden City, Herts, England

[14] AbbVie, N Chicago, IL USA

[15] Roche Prod Ltd, Welwyn Garden City, Herts, England

[16] Univ Claude Bernard Lyon 1, Hosp Civils Lyon, CHU Lyon Sud, Dept Hematol, Pierre Benite, France

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-118362

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1859

引用

页数：5

共 50 条

[1] Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/ Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Stilgenbauer, Stephan
Morschhauser, Franck
Wendtner, Clemens-Martin
Cartron, Guillaume
Hallek, Michael
Eichhorst, Barbara F.
Kozloff, Mark
Giever, Thomas A.
Lozanski, Gerard
Punnoose, Elizabeth A.
Wang, Jue
Hilger, James
Mobasher, Mehrdad
Salles, Gilles
BLOOD, 2016, 128 (22)
[2] Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
Stilgenbauer, Stephan
Morschhauser, Franck
Wendtner, Clemens-Martin
Cartron, Guillaume
Hallek, Michael
Eichhorst, Barbara
Kozloff, Mark F.
Giever, Thomas
Lozanski, Gerard
Jiang, Yanwen
Huang, Huang
Pignataro, Daniela Soriano
Schary, William
Humphrey, Kathryn
Mobasher, Mehrdad
Salles, Gilles
HAEMATOLOGICA, 2021, 106 (11) : 2834 - 2844
[3] Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL).
Sharman, Jeff Porter
Yimer, Habte Aragaw
Boxer, Michael
DiBella, Nicholas
Babu, Sunil
Li, Jia
Mun, . . . Yong Jun
Skettino, Sandra L.
Danilov, Alexey Valeryevich
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Lampson, Benjamin L.
Tyekucheva, Svitlana
Crombie, Jennifer L.
Kim, Austin I.
Merryman, Reid W.
Lowney, Jessica
Montegaard, Josie
Patterson, Victoria
Jacobson, Caron A.
Jacobsen, Eric D.
LaCasce, Ann S.
Arnason, Jon E.
Armand, Philippe
Fisher, David C.
Brown, Jennifer R.
Davids, Matthew S.
BLOOD, 2019, 134
[5] RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
Danilov, A.
Yimer, H.
Boxer, M.
Di Bella, N.
Babu, S.
Li, J.
Mun, Y.
Skettino, S.
Sharman, J.
HAEMATOLOGICA, 2017, 102 : 71 - 71
[6] Preliminary Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Awan, Farrukh T.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 6 - 8
[7] Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study
Stilgenbauer, Stephan
Ilhan, Osman
Woszczyk, Darius
Renner, Christoph
Mikuskova, Eva
Boettcher, Sebastian
Tausch, Eugen
Moore, Tom
Tyson, Nicola
Adamis, Helena
Leblonde, Veronique
Bosch, Francesc
Foa, Robin
BLOOD, 2015, 126 (23)
[8] Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Salles, Gilles Andre
Boyd, Thomas E.
Morschhauser, Franck
Wendtner, Clemens-Martin
Lymp, James
Hilger, James
Vosganian, Gregory
Huang, Jane
Stilgenbauer, Stephan
BLOOD, 2014, 124 (21)
[9] Bendamustine in Combination with Rituximab for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients: An Italian Retrospective Multicentre Study
Gentile, Massimo
Ciolli, Stefania
Molica, Stefano
Di Renzo, Nicola
Selleri, Carmine
Villa, Maria Rosaria
De Paolis, Maria Rosaria
Scortechini, Ilaria
Giannotta, Angela
Minoia, Carla
Rago, Angela
Boncompagni, Riccardo
Bonanno, Vincenza
Levato, Luciano
Musso, Maurizio
Mastrullo, Lucia
Melpignano, Angela
Murru, Roberta
Angelucci, Emanuele
Tarantini, Giuseppe
Caparrotti, Giuseppe
Guarini, Attilio
Ferrara, Felicetto
Cimino, Giuseppe
Zinzani, Pier Luigi
Morabito, Fortunato
BLOOD, 2014, 124 (21)
[10] Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
Flinn, Ian W.
Gribben, John G.
Dyer, Martin J. S.
Wierda, William G.
Maris, Michael B.
Furman, Richard R.
Hillmen, Peter
Jones, Jeffrey
Iyer, Swami P.
Jones, Surai
Jiang, Yanwen
Pignataro, Daniela Soriano
Humphrey, Kathryn
Mobasher, Mehrdad
Kipps, Thomas J.
BLOOD, 2017, 130

← 1 2 3 4 5 →